Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen

被引：0
|
作者：
M. van Nuland
R. A. Vreman
R. M. T. ten Ham
A. H. M. de Vries Schultink
H. Rosing
J. H. M. Schellens
J. H. Beijnen
A. M. Hövels
机构：
[1] The Netherlands Cancer Institute and MC Slotervaart,Department of Pharmacy and Pharmacology
[2] The Netherlands Cancer Institute,Division of Pharmacology
[3] Utrecht University,Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences
[4] The Netherlands Cancer Institute,Division of Clinical Pharmacology, Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2018年 / 172卷
关键词：
Therapeutic drug monitoring; Cost-effectiveness; Tamoxifen; Endoxifen; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：143 / 150
页数：7
相关论文
共 50 条
  • [21] Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
    Braal, C. Louwrens
    Kleijburg, Anne
    Jager, Agnes
    Koolen, Stijn L. W.
    Mathijssen, Ron H. J.
    Ramos, Isaac Corro
    Wetzelaer, Pim
    Uyl-de Groot, Carin A.
    CLINICAL DRUG INVESTIGATION, 2022, 42 (02) : 163 - 175
  • [22] Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram
    Haji, Elnaz Ostad
    Mann, Klaus
    Dragicevic, Aleksandra
    Mueller, Matthias J.
    Boland, Katja
    Rao, Marie-Luise
    Fric, Miriam
    Laux, Gerd
    Hiemke, Christoph
    THERAPEUTIC DRUG MONITORING, 2013, 35 (03) : 396 - 401
  • [23] Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
    ten Ham, Renske M. T.
    van Nuland, Merel
    Vreman, Rick A.
    de Graaf, Laurens G.
    Rosing, Hilde
    Bergman, Andre M.
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    Hovels, Anke M.
    VALUE IN HEALTH, 2021, 24 (01) : 121 - 128
  • [24] Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
    Schroth, Werner
    Winter, Stefan
    Muerdter, Thomas
    Schaeffeler, Elke
    Eccles, Diana
    Eccles, Bryony
    Chowbay, Balram
    Khor, Chiea C.
    Tfayli, Arafat
    Zgheib, Nathalie K.
    Eichelbaum, Michel
    Schwab, Matthias
    Brauch, Hiltrud
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [25] Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
    C. Louwrens Braal
    Koen G. A. M. Hussaarts
    Lieke Seuren
    Esther Oomen‑deHoop
    Peter de Bruijn
    ·Stefan A. J. Buck
    Monique E. M. M. Bos
    Martine F. Thijs‑Visser
    Hanneke J. M. Zuetenhorst
    Daniëlle Mathijssen‑van Stein
    Mijntje B. Vastbinder
    Roelof W. F. van Leeuwen
    Teun van Gelder
    Stijn L. W. Koolen
    Agnes Jager
    Ron H. J. Mathijssen
    Breast Cancer Research and Treatment, 2021, 185 : 889 - 889
  • [26] Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation
    Fox, Peter
    Gao, Bo
    Balakrishnar, Bavanthi
    Menzies, Alexander M.
    Yeap, Shang Heng
    Ali, Sayed Sahanawaz
    Gebski, Val
    Provan, Pamela
    Coulter, Sally
    Liddle, Christopher
    Hui, Rina
    Kefford, Richard
    Lynch, Jodi
    Wilcken, Nicholas
    Balleine, Rosemary L.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Prospective Assessment of CYP2D6 by Genotyping, Phenotyping and Measurement of Tamoxifen, 4-Hydroxy-Tamoxifen and Endoxifen in Breast Cancer Patients Treated with Tamoxifen
    Zaman, K.
    Dahmane, E.
    Csajka, C.
    Perey, L.
    Buclin, T.
    Bodmer, A.
    Leyvraz, S.
    Rindisbacher, M. Galmiche
    Berthod, G.
    Chin, E.
    Decosterd, L.
    CANCER RESEARCH, 2010, 70
  • [28] FACTORS PREDICTING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS TAKING STANDARD-DOSE TAMOXIFEN AND FOLLOWING DOSE ESCALATION
    Fox, P.
    Gao, B.
    Balakrishnar, B.
    Menzies, A.
    Gebski, V.
    Provan, P.
    Coulter, S.
    Liddle, C.
    Hui, R.
    Kefford, R.
    Lynch, J.
    Wilcken, N.
    Balleine, R.
    Gurney, H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 45 - 45
  • [29] Cost-effectiveness of breast cancer screening in Spain
    Plans, P
    Casademont, L
    Salleras, L
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1996, 12 (01) : 146 - 150
  • [30] THE COST-EFFECTIVENESS OF BREAST-CANCER SCREENING
    Van Der Maas, PJ
    DEKONING, HJ
    VANINEVELD, BM
    VANOORTMARSSEN, GJ
    HABBEMA, JDF
    LUBBE, KTN
    GEERTS, AT
    COLLETTE, HJA
    VERBEEK, ALM
    HENDRIKS, JHCL
    ROMBACH, JJ
    INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (06) : 1055 - 1060
12345